Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:
- H.C. Wainwright 4th Annual NASH Investor Conference
Monday, October 5, 2020 – 3:30 pm ET
- Guggenheim Securities’ 1st Annual Vaccines & Infectious Diseases Day
Monday, October 5, 2020 – 4:45 pm ET
The H.C. Wainwright presentation will be webcast and can be accessed by visiting the investor relations section of the company’s website at www.altimmune.com under Events/Presentations.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.
Investor Contacts: